Doripenem vs meropenem against Pseudomonas and Acinetobacter

Indian Journal of Medical Microbiology

Volumn 30, Issue 3, 2012, Pages 350-351

  Goyal, K ^a   Gautam, V ^a   Ray, P ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Acinetobacter; doripenem; meropenem; MIC; Pseudomonas

Indexed keywords

DORIPENEM; MEROPENEM;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; EPSILOMETER TEST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; TRACHEAL ASPIRATION PROCEDURE; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84865610809     PISSN: 02550857     EISSN: 19983646     Source Type: Journal    
DOI: 10.4103/0255-0857.99502     Document Type: Article

References (6)

1. Schafer JJ, Goff DA, Mangino JE. Doripenem: A new addition to the carbapenem class of antimicrobials. Recent Pat Antiinfect Drug Discov 2009;4:18-28.
2. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009;49:291-8.
3. European Committee on Antimicrobial Susceptibility testing. EUCAST recommended strains for internal quality control. Version 1.0. Available from: www.eucast.org. 4. Chatterjee SS, Karmacharya R, Madhup SK, Gautam V, Das A, Ray P. High prevalence of co-expression of newer beta-lactamases (ESBLs, Amp-C-beta-lactamases, and metallo-beta-lactamases) in gram-negative bacilli. Indian J Med Microbiol 2010;28:267-8.
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
5. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother 2004;54:144-54.
6. Wilke MH. Multiresistant bacteria and current therapy - the economical side of the story. Eur J Med Res 2010;15:571-6.